|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RAD51B |
Gene summary for RAD51B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RAD51B | Gene ID | 5890 |
| Gene name | RAD51 paralog B | |
| Gene Alias | R51H2 | |
| Cytomap | 14q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O15315 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5890 | RAD51B | CCI_1 | Human | Cervix | CC | 1.18e-27 | 1.84e+00 | 0.528 |
| 5890 | RAD51B | CCI_2 | Human | Cervix | CC | 5.52e-08 | 6.87e-01 | 0.5249 |
| 5890 | RAD51B | CCI_3 | Human | Cervix | CC | 2.72e-27 | 1.38e+00 | 0.516 |
| 5890 | RAD51B | CCII_1 | Human | Cervix | CC | 2.11e-04 | 3.30e-01 | 0.3249 |
| 5890 | RAD51B | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.60e-03 | -1.95e-01 | 0.0216 |
| 5890 | RAD51B | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.89e-02 | 4.98e-01 | -0.0811 |
| 5890 | RAD51B | HTA11_78_2000001011 | Human | Colorectum | AD | 2.34e-03 | 5.63e-01 | -0.1088 |
| 5890 | RAD51B | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.40e-04 | 6.09e-01 | -0.059 |
| 5890 | RAD51B | HTA11_6801_2000001011 | Human | Colorectum | SER | 8.48e-03 | -6.27e-01 | 0.0171 |
| 5890 | RAD51B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.80e-26 | 1.51e+00 | 0.281 |
| 5890 | RAD51B | A015-C-203 | Human | Colorectum | FAP | 2.85e-25 | -4.88e-01 | -0.1294 |
| 5890 | RAD51B | A015-C-204 | Human | Colorectum | FAP | 2.43e-04 | -3.61e-01 | -0.0228 |
| 5890 | RAD51B | A014-C-040 | Human | Colorectum | FAP | 4.96e-03 | -3.30e-01 | -0.1184 |
| 5890 | RAD51B | A002-C-201 | Human | Colorectum | FAP | 2.26e-08 | -3.80e-01 | 0.0324 |
| 5890 | RAD51B | A001-C-119 | Human | Colorectum | FAP | 4.51e-10 | -6.62e-01 | -0.1557 |
| 5890 | RAD51B | A001-C-108 | Human | Colorectum | FAP | 2.26e-11 | -3.19e-01 | -0.0272 |
| 5890 | RAD51B | A002-C-205 | Human | Colorectum | FAP | 5.45e-24 | -5.90e-01 | -0.1236 |
| 5890 | RAD51B | A015-C-005 | Human | Colorectum | FAP | 3.03e-03 | -3.63e-01 | -0.0336 |
| 5890 | RAD51B | A015-C-006 | Human | Colorectum | FAP | 1.18e-12 | -4.76e-01 | -0.0994 |
| 5890 | RAD51B | A015-C-106 | Human | Colorectum | FAP | 4.17e-06 | -1.67e-01 | -0.0511 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
| GO:00457876 | Cervix | CC | positive regulation of cell cycle | 66/2311 | 313/18723 | 7.78e-06 | 1.81e-04 | 66 |
| GO:00073466 | Cervix | CC | regulation of mitotic cell cycle | 88/2311 | 457/18723 | 1.26e-05 | 2.60e-04 | 88 |
| GO:19019903 | Cervix | CC | regulation of mitotic cell cycle phase transition | 63/2311 | 299/18723 | 1.27e-05 | 2.60e-04 | 63 |
| GO:00459316 | Cervix | CC | positive regulation of mitotic cell cycle | 32/2311 | 121/18723 | 1.88e-05 | 3.47e-04 | 32 |
| GO:19019922 | Cervix | CC | positive regulation of mitotic cell cycle phase transition | 26/2311 | 93/18723 | 3.97e-05 | 6.18e-04 | 26 |
| GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
| GO:00900685 | Cervix | CC | positive regulation of cell cycle process | 50/2311 | 236/18723 | 8.25e-05 | 1.11e-03 | 50 |
| GO:19019873 | Cervix | CC | regulation of cell cycle phase transition | 74/2311 | 390/18723 | 9.80e-05 | 1.27e-03 | 74 |
| GO:19019892 | Cervix | CC | positive regulation of cell cycle phase transition | 28/2311 | 115/18723 | 2.82e-04 | 3.07e-03 | 28 |
| GO:1902751 | Cervix | CC | positive regulation of cell cycle G2/M phase transition | 11/2311 | 30/18723 | 5.71e-04 | 5.45e-03 | 11 |
| GO:0010971 | Cervix | CC | positive regulation of G2/M transition of mitotic cell cycle | 10/2311 | 27/18723 | 9.25e-04 | 7.84e-03 | 10 |
| GO:00448392 | Cervix | CC | cell cycle G2/M phase transition | 31/2311 | 148/18723 | 2.07e-03 | 1.51e-02 | 31 |
| GO:00000862 | Cervix | CC | G2/M transition of mitotic cell cycle | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
| GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
| GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
| GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
| GO:0045787 | Colorectum | AD | positive regulation of cell cycle | 85/3918 | 313/18723 | 4.76e-03 | 3.22e-02 | 85 |
| GO:0045931 | Colorectum | AD | positive regulation of mitotic cell cycle | 37/3918 | 121/18723 | 7.88e-03 | 4.73e-02 | 37 |
| GO:00017011 | Colorectum | SER | in utero embryonic development | 77/2897 | 367/18723 | 2.77e-03 | 2.48e-02 | 77 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RAD51B | SNV | Missense_Mutation | c.751N>G | p.Ile251Val | p.I251V | protein_coding | tolerated(0.05) | benign(0.207) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| RAD51B | SNV | Missense_Mutation | c.189N>T | p.Lys63Asn | p.K63N | protein_coding | tolerated(0.11) | benign(0.422) | TCGA-EW-A1IX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | femara | SD | ||
| RAD51B | deletion | Frame_Shift_Del | novel | c.1197_1200delAACT | p.Thr400SerfsTer29 | p.T400Sfs*29 | protein_coding | TCGA-DG-A2KJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |||
| RAD51B | SNV | Missense_Mutation | c.982G>T | p.Ala328Ser | p.A328S | protein_coding | tolerated(0.45) | possibly_damaging(0.451) | TCGA-AA-A02J-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
| RAD51B | SNV | Missense_Mutation | novel | c.120G>T | p.Lys40Asn | p.K40N | protein_coding | deleterious(0.03) | benign(0.316) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RAD51B | SNV | Missense_Mutation | c.111N>T | p.Glu37Asp | p.E37D | protein_coding | tolerated(0.17) | benign(0.263) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | ||
| RAD51B | SNV | Missense_Mutation | novel | c.653A>C | p.Lys218Thr | p.K218T | protein_coding | tolerated(0.11) | benign(0.285) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RAD51B | SNV | Missense_Mutation | novel | c.521N>T | p.Ser174Ile | p.S174I | protein_coding | deleterious(0.01) | benign(0.029) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| RAD51B | SNV | Missense_Mutation | novel | c.578A>C | p.Glu193Ala | p.E193A | protein_coding | deleterious(0.02) | benign(0.238) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
| RAD51B | SNV | Missense_Mutation | novel | c.398N>A | p.Gly133Glu | p.G133E | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |